Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Mapping the journey to an HIV vaccine.

Ackerman M, Alter G.

N Engl J Med. 2013 Jul 25;369(4):389-91. doi: 10.1056/NEJMcibr1304437. No abstract available.

2.

AIDS/HIV. A boost for HIV vaccine design.

Burton DR, Weiss RA.

Science. 2010 Aug 13;329(5993):770-3. doi: 10.1126/science.1194693. No abstract available.

PMID:
20705840
3.

PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.

Fauci AS, Marston HD.

Science. 2015 Jul 24;349(6246):386-7. doi: 10.1126/science.aac6300. Epub 2015 Jul 23. No abstract available.

PMID:
26206922
4.

HIV vaccine development--improving on natural immunity.

Johnston MI, Fauci AS.

N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621. No abstract available.

5.

A pathway to HIV-1 neutralization breadth.

Smith SA, Derdeyn CA.

Nat Med. 2015 Nov;21(11):1246-7. doi: 10.1038/nm.3989. No abstract available.

6.

Challenges for structure-based HIV vaccine design.

Schief WR, Ban YE, Stamatatos L.

Curr Opin HIV AIDS. 2009 Sep;4(5):431-40. doi: 10.1097/COH.0b013e32832e6184. Review.

PMID:
20048708
7.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
8.

Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.

Parsons MS, Rouleau D, Routy JP, LeBlanc R, Grant MD, Bernard NF.

AIDS. 2011 Jun 19;25(10):1249-64. doi: 10.1097/QAD.0b013e328347f9fa.

PMID:
21516028
9.

HIV: Roadmaps to a vaccine.

Mouquet H, Nussenzweig MC.

Nature. 2013 Apr 25;496(7446):441-2. doi: 10.1038/nature12091. Epub 2013 Apr 3. No abstract available.

PMID:
23552894
10.
11.

Lessons learned from HIV-1 vaccine trials: new priorities and directions.

McMichael AJ, Haynes BF.

Nat Immunol. 2012 Apr 18;13(5):423-7. doi: 10.1038/ni.2264. Erratum in: Nat Immunol. 2013 Apr;14(4):413.

12.

HIV vaccine design: the neutralizing antibody conundrum.

Stamatatos L.

Curr Opin Immunol. 2012 Jun;24(3):316-23. doi: 10.1016/j.coi.2012.04.006. Epub 2012 May 15. Review. No abstract available.

PMID:
22595693
13.

"Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies.

Dimitrov JD, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

PLoS Pathog. 2011 Jun;7(6):e1002095. doi: 10.1371/journal.ppat.1002095. Epub 2011 Jun 16. Review. No abstract available.

14.

Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1.

Kwong PD, Mascola JR, Nabel GJ.

Cell Host Microbe. 2009 Oct 22;6(4):292-4. doi: 10.1016/j.chom.2009.09.008.

15.

Broadly Neutralizing Antibodies and the Development of Vaccines.

Haynes BF, Bradley T.

JAMA. 2015 Jun 23-30;313(24):2419-20. doi: 10.1001/jama.2015.2427. No abstract available.

PMID:
26103022
16.

Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.

Liu L, Wan Y, Wu L, Sun J, Li H, Li H, Ma L, Shao Y.

Retrovirology. 2010 Sep 1;7:71. doi: 10.1186/1742-4690-7-71.

17.

B cell liaison confounds HIV-1 evolution.

McHeyzer-Williams MG.

Cell. 2014 Jul 31;158(3):475-6. doi: 10.1016/j.cell.2014.07.018.

18.

Broadly neutralizing antibodies and their significance for HIV-1 vaccines.

González N, Alvarez A, Alcamí J.

Curr HIV Res. 2010 Dec;8(8):602-12. Review.

PMID:
21054253
19.

HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Doria-Rose NA.

J Infect Dis. 2010 Apr 1;201(7):981-3. doi: 10.1086/651143. No abstract available.

20.

Vaccines to antibodies: grow up!

von Bubnoff A.

IAVI Rep. 2010 Jul-Aug;14(4):4-9.

Supplemental Content

Support Center